Therefore, we suggest that targeting the SphK1/S1P signaling represents a strategy that could potentially be exploited in therapeutic approaches to decrease HIF-2 activity in cancer and more particularly in ccRCC. Here, SPHK1 is linked to nonpapillary renal cell carcinoma.